^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) + cyclophosphamide (Alkylating agent) + Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer
Published date:
04/04/2022
Excerpt:
We prospectively studied stage II/III BC patients who were eligible for breast-conserving surgery. Patients received epirubicin and cyclophosphamide for 4 cycles, followed by another 4-cycle docetaxel, and human epidermal growth factor receptor (HER2) positive patients were additionally treated with herceptin when using docetaxel (EC-T(H))....PIK3CA (48%) and TP53 (40%) mutations were enriched in patients not achieving pCR.
DOI:
10.3389/fonc.2021.784985
